LTRN — Lantern Pharma Share News
0.000.00%
Last trade - 00:00Brief: Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress
U.S. STOCKS ON THE MOVE-Hershey, Eli Lilly, energy stocks
U.S. STOCKS ON THE MOVE-Aqua Metals, Corbus Pharma, Micron
Lantern Pharma rises after early-stage trial win for its cancer drug
Brief: IBN’s BioMedWire Podcast Features Lantern Pharma CEO on AI-Driven Cancer Breakthroughs
Brief: Lantern Pharma Completes FDA Type C Meeting On Pediatric CNS Cancer Trial
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Inc expected to post a loss of 48 cents a share - Earnings Preview
Lantern Pharma Inc expected to post a loss of 48 cents a share - Earnings Preview
Brief: Lantern Pharma Completes Targeted Enrollment For Lung Cancer Phase 2 Harmonic™ Clinical Trial In Japan For LP-300
Brief: Lantern Pharma Announces Appointment Of Dr. Lee Schalop To Board Of Directors
Brief: Lantern Pharma Reports Complete Response In Heavily Pre-Treated Lymphoma Patient In Phase 1 Clinical Trial
Brief: Lantern Pharma May Sell Shares for Up to $15.5 Million via Sales Agent
Brief: Lung Cancer Patient In Lantern Pharma’s Harmonic Trial Shows Durable Complete Response In Target Cancer Lesions With Survival Continuing For Nearly Two Years
Brief: Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors at SNO Pediatric Conference
Lantern Pharma Inc reports results for the quarter ended March 31 - Earnings Summary
Lantern Pharma Inc expected to post a loss of 49 cents a share - Earnings Preview
Lantern Pharma Inc expected to post a loss of 49 cents a share - Earnings Preview
Brief: Lantern Pharma Inc Qtrly EPS $-0.54